Vifor Fresenius Medical Care Renal Pharma

April 28, 2022 Off

Vifor-Cara Therapeutics’s Kapruvia Approved for Treatment of Moderate-to-Severe Pruritus in Hemodialysis in EU

By Author

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have announced that the European Commission has granted marketing authorization to Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients.

February 28, 2022 Off

Kapruvia Receives Positive CHMP Opinion for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients

By Dino Mustafić

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, have announced that the European Medicines Agency’s (EMA) CHMP has recommended…

May 18, 2020 Off

Avacopan new focus for VFMCRP and ChemoCentryx, CCX140 won’t move forward in FSGS

By BusinessWire

In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.